Midodrine

Medical uses

Midodrine is indicated for the treatment of symptomatic orthostatic hypotension. It can reduce dizziness and faints by about a third, but can be limited by troublesome goose bumps, skin itch, gastrointestinal discomfort, chills, elevated blood pressure while lying down, and urinary retention. A meta-analysis of clinical trials of midodrine or droxidopa in patients with low blood pressure when standing found that midodrine increased standing blood pressure more than droxidopa but that midodrine but not droxidopa increased the risk of high blood pressure when lying down. Small studies have also shown that midodrine can be used to prevent excessive drops in blood pressure in people requiring dialysis.

Midodrine has been used in the complications of cirrhosis. It is also used with octreotide for hepatorenal syndrome; the proposed mechanism is constriction of splanchnic vessels and dilation of renal vasculature. Studies have not been sufficiently well conducted to show a clear place for midodrine.

Midodrine is used off-label to increase blood pressure in the treatment of postural orthostatic tachycardia syndrome (POTS) where increased transduction of venous alpha 1 adrenergic receptors increases venous return.

Available forms

Midodrine is available in the form of 2.5, 5, and 10mg oral tablets.

Contraindications

Midodrine is contraindicated in people with severe organic heart disease, acute kidney disease, urinary retention, pheochromocytoma or thyrotoxicosis.

Side effects

Headache, feeling of pressure or fullness in the head, vasodilation or flushing face, scalp tingling, confusion or thinking abnormality, dry mouth, anxiety, and rash, among others.

Pharmacology

Pharmacodynamics

Midodrine is a prodrug which forms the active metabolite, desglymidodrine, which is an α1-adrenergic receptor agonist and exerts its actions via activation of α1-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure. Desglymidodrine does not stimulate cardiac β-adrenergic receptors.

Pharmacokinetics

After oral administration, midodrine is rapidly absorbed. The plasma levels of the prodrug peak after about half an hour, and decline with a half-life of approximately 25minutes, while the metabolite reaches peak blood concentrations about 1 to 2 hours after a dose of midodrine and has a half-life of about 3 to4 hours. The absolute bioavailability of midodrine (measured as desglymidodrine) is 93%.

Midodrine and desglymidodrine diffuse poorly across the blood–brain barrier and are therefore peripherally selective and are not associated with effects in the central nervous system.

Neither midodrine nor desglymidodrine are substrates of monoamine oxidase.

Chemistry

Midodrine, also known as 3,6-dimethoxy-β-hydroxy-N-aminoethanonyl-2-phenylethylamine, is a substituted phenethylamine derivative.

Midodrine is an odorless, white, crystalline powder, soluble in water and sparingly soluble in methanol.

Midodrine's experimental log P is -0.5 and its predicted log P ranges from -0.49 to -0.95. The predicted log P of its active metabolite desglymidodrine ranges from -0.01 to 0.15.

Stereochemistry

Midodrine contains a stereocenter and consists of two enantiomers, making it a racemate; i.e., a 1:1 mixture of (R)- and (S)-forms:

Synthesis

Acylation of 1,4-dimethoxybenzene with chloroacetyl chloride gives the chloroketone 2. The halogen is then converted to the amine 3 by any set of standard schemes, and the ketone reduced to an alcohol with borohydride (4). Acylation of the amino group in this last intermediate with chloroacetyl chloride affords the amide 5. The halogen is then displaced with azide and the resulting product 6 reduced catalytically to the glycinamide, midodrine (7).

History

Midodrine was discovered by 1971. It was approved in the United States by the Food and Drug Administration (FDA) in 1996 for the treatment of dysautonomia and orthostatic hypotension.

In August 2010, the FDA proposed withdrawing this approval because the manufacturer, Shire plc, failed to complete required studies after the medicine reached the market. In September 2010, the FDA reversed its decision to remove midodrine from the market and allowed it to remain available while Shire plc collected further data regarding the efficacy and safety of the drug. Shire announced in September 2011, that it was withdrawing completely from supplying midodrine. Midodrine remains available as a generic drug.

Society and culture

Names

Midodrine is the generic name of the drug and its international nonproprietary name and British Approved Name. In the case of the hydrochloride salt, its generic name is midodrine hydrochloride and this is its United States Adopted Name, British Approved Name, and Japanese Accepted Name. Midodrine is also known by its developmental code names ST-1085 and TS-701. Midodrine has been sold under brand names including Amatine, Gutron, Midamine, Midon, and Proamatine, among others.

References

References

1. "Proamatine- midodrine hydrochloride tablet".
2. (2004). "Primer on the Autonomic Nervous System". Elsevier.
3. (May 2020). "Real-world droxidopa or midodrine treatment persistence in patients with neurogenic orthostatic hypotension or orthostatic hypotension". Autonomic Neuroscience.
4. (September 2014). "Midodrine for orthostatic hypotension and recurrent reflex syncope: A systematic review". Neurology.
5. (December 2018). "Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials". The Annals of Pharmacotherapy.
6. (October 2004). "Midodrine appears to be safe and effective for dialysis-induced hypotension: a systematic review". Nephrology, Dialysis, Transplantation.
7. (April 2009). "Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications". The Annals of Pharmacotherapy.
8. (October 2022). "Postural orthostatic tachycardia syndrome: pathophysiology, management, and experimental therapies". Expert Opin Investig Drugs.
9. (May 2023). "Choices and Challenges With Drug Therapy in Postural Orthostatic Tachycardia Syndrome: A Systematic Review". Cureus.
10. (December 2012). "Postural tachycardia syndrome: a heterogeneous and multifactorial disorder". Mayo Clin Proc.
11. (31 December 1992). "Midodrine: Uses, Interactions, Mechanism of Action".
12. (December 2022). "Midodrine use in critically ill patients: a narrative review". Crit Care Resusc.
13. (May 2000). "Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension". Expert Opin Pharmacother.
14. (January 1998). "Midodrine. A review of its therapeutic use in the management of orthostatic hypotension". Drugs Aging.
15. "Midodrine".
16. "Desglymidodrine".
17. Rote Liste Service GmbH (Hrsg.): ''Rote Liste 2017 – Arzneimittelverzeichnis für Deutschland (einschließlich EU-Zulassungen und bestimmter Medizinprodukte)''. Rote Liste Service GmbH, Frankfurt/Main, 2017, Aufl. 57, {{ISBN. 978-3-946057-10-9, S. 196.
18. (2000-03-20). "Acetylation of dimethoxybenzenes with acetic anhydride in the presence of acidic zeolites". Journal of Molecular Catalysis A: Chemical.
19. (2022-01-01). "Comprehensive Heterocyclic Chemistry IV". Elsevier.
20. "Phenylethanolamine derivs prepn. - by reducing azides, useful as hypertensives".
21. K. Wismayr et al., {{Cite patent. 3340298 (1965, 1967 both to Chemie Linz Ag).
22. Zoelss & W. Karl-Anton Ing {{Cite patent
23. [https://archive.today/20120720172637/http://uk.reuters.com/article/idUKTRE67F3SE20100816 U.S. proposes withdrawal of Shire hypotension drug], 16 August 2010.
24. "FDA recommends withdrawal of midodrine". TheHeart.org.
25. [http://healthcare.utah.edu/pharmacy/alerts/497.htm Midodrine (Proamatine, generic) Proposed Market Withdrawal – Update] {{Webarchive. link. (28 March 2012 10 September 2010.)
26. "Shire Provides Update on Proamatine (midodrine HCl)". Shire plc.
27. (2014). "The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies". Springer US.
28. (2012). "Concise Dictionary of Pharmacological Agents: Properties and Synonyms". Springer Netherlands.
29. Schweizerischer Apotheker-Verein. (2004). "Index Nominum: International Drug Directory". Medpharm Scientific Publishers.
30. (1990). "Drugs Available Abroad: A Guide to Therapeutic Drugs Available and Approved for Use Outside the U. S.". Gale Research.